Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis

Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis

Background: Clinical efficacy of zilucoplan has been demonstrated in a 12-week, placebo-controlled, phase III study in patients with acetylcholine receptor autoantibody-positive generalised myasthenia gravis (gMG). However, placebo-controlled zilucoplan data past 12 weeks are not available. Objectiv...

Descripció completa

Dades bibliogràfiques
Autors principals: Guillemette de la Borderie, Damien Chimits, Babak Boroojerdi, Melissa Brock, Petra W. Duda, Fiona Grimson, Paul Mahoney, Foteini Strimenopoulou, Gary Cutter, Inmaculada Aban, Susanna Brauner, Malin Petersson, James F. Howard, Nathan Bennett
Format: Article
Idioma:English
Publicat: SAGE Publishing 2024-09-01
Col·lecció:Therapeutic Advances in Neurological Disorders
Accés en línia:https://doi.org/10.1177/17562864241279125

Internet

https://doi.org/10.1177/17562864241279125

Ítems similars